ESPR - Esperion Therapeutics, Inc.

QQQ $ 455.25 $ 5.77 (1.29 %)

DIA $ 409.08 $ 4.58 (1.13 %)

SPY $ 546.60 $ 6.05 (1.12 %)

TLT $ 99.96 $ 0.43 (0.43 %)

GLD $ 231.58 $ 0.97 (0.42 %)

Previous Close

$ 1.7

Open

$ 1.66

Bid

$ 1.70 x 4,800

Ask

$ 1.71 x 4,900

Day's Range

$ 1.65 - $ 1.75

52 Week Range

$ 0.70 - $ 3.40

Volume

2,027,224

Average Volume

Market Cap

333.58M

Beta (5Y Monthly)

$ 0.88

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-27-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-01-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	02-21-2023	12-31-2022	10-K
8	11-01-2022	09-30-2022	10-Q
9	08-02-2022	06-30-2022	10-Q
10	05-03-2022	03-31-2022	10-Q
11	02-22-2022	12-31-2021	10-K
12	11-02-2021	09-30-2021	10-Q
13	08-03-2021	06-30-2021	10-Q
14	05-04-2021	03-31-2021	10-Q
15	02-23-2021	12-31-2020	10-K
16	11-02-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-06-2020	03-31-2020	10-Q
19	02-27-2020	12-31-2019	10-K
20	11-06-2019	09-30-2019	10-Q
21	08-08-2019	06-30-2019	10-Q
22	05-08-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	11-01-2018	09-30-2018	10-Q
25	08-02-2018	06-30-2018	10-Q
26	05-02-2018	03-31-2018	10-Q
27	02-20-2018	12-31-2017	10-K
28	11-07-2017	09-30-2017	10-Q
29	08-08-2017	06-30-2017	10-Q
30	05-04-2017	03-31-2017	10-Q
31	02-22-2017	12-31-2016	10-K
32	11-03-2016	09-30-2016	10-Q
33	08-04-2016	06-30-2016	10-Q
34	05-04-2016	03-31-2016	10-Q
35	02-25-2016	12-31-2015	10-K
36	11-05-2015	09-30-2015	10-Q
37	08-06-2015	06-30-2015	10-Q
38	05-07-2015	03-31-2015	10-Q
39	03-10-2015	12-31-2014	10-K
40	11-10-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Esperion Secures Additional Commercial And...
09/03/2024 12:18:43

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More T...

Needham Maintains Buy on Esperion Therapeu...
08/13/2024 10:02:19

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $8 ...

HC Wainwright & Co. Reiterates Buy on Espe...
08/12/2024 17:55:11

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

why-ainos-shares-are-trading-higher-by-around-38-here-are-20-stocks-moving-premarket

Why Ainos Shares Are Trading Higher By Aro...
08/12/2024 10:04:36

Esperion Reiterates Its Full Year 2024 Ope...
08/12/2024 10:02:49

Esperion Therapeutics Q2 2024 GAAP EPS $(0...
08/12/2024 10:01:26

Needham Reiterates Buy on Esperion Therape...
06/28/2024 17:32:37

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.

HC Wainwright & Co. Reiterates Buy on Espe...
06/28/2024 15:08:29

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

Esperion Therapeutics shares are trading h...
06/28/2024 11:39:06

Esperion Says It Enters Into A Royalty Pur...
06/28/2024 11:06:13

why-jabil-shares-are-trading-lower-by-8-here-are-other-stocks-moving-in-thursdays-mid-day-session

Why Jabil Shares Are Trading Lower By 8%? ...
06/20/2024 17:26:29

workday-to-rally-over-52-here-are-10-top-analyst-forecasts-for-thursday

Workday To Rally Over 52%? Here Are 10 Top...
06/20/2024 12:11:28

B of A Securities Downgrades Esperion Ther...
06/20/2024 10:36:03

B of A Securities analyst Jason Zemansky downgrades Esperion Therapeutics (NASDAQ:ESPR) from Neutral to Underperform and low...

why-skye-bioscience-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Skye Bioscience Shares Are Trading Low...
06/10/2024 18:10:40

argan-reports-strong-earnings-joins-geron-planet-labs-pbc-and-other-big-stocks-moving-higher-on-friday

Argan Reports Strong Earnings, Joins Geron...
06/07/2024 14:19:37

HC Wainwright & Co. Reiterates Buy on Espe...
05/22/2024 15:59:51

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

European Commission Approve NILEMDO And It...
05/22/2024 12:08:01

– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) R...

HC Wainwright & Co. Reiterates Buy on Espe...
05/21/2024 09:42:24

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

esperion-therapeuticsotsuka-partnered-cholesterol-drug-shows-effective-in-japan-study

Esperion Therapeutics/Otsuka Partnered Cho...
05/20/2024 18:22:42

Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant...

Esperion, Otsuka Report Primary Endpoint W...
05/20/2024 10:02:32

The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potent...